EGFR and glioblastoma: Altogether, these data highlight that EGFR inhibition, through monoclonal antibodies or TKI combined with other chemotherapeutics could be a potential and prominent therapeutic strategy in the treatment of neurodegeneration and neuronal pathological diseases, including GBM progression.